10-Q: Q2 2024 Earnings Report
8-K: Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
8-K: Current report
424B5: Prospectus
8-K: Current report
424B5: Prospectus
8-K: Current report
4: Statement of changes in beneficial ownership of securities-Officer Clifton R. LaDuane
4: Statement of changes in beneficial ownership of securities-Director Anderson Thomas
4: Statement of changes in beneficial ownership of securities-Director Bode John B
8-K: Current report
424B2: Prospectus
8-K: Current report
4: Statement of changes in beneficial ownership of securities-Officer Thompson Rahsaan
3: Initial statement of beneficial ownership of securities-Officer Thompson Rahsaan
EFFECT: Others
CORRESP: CORRESP
UPLOAD: Others
S-3: Registration statement for specified transactions by certain issuers
8-K: Current report
No Data